Investigational drug · Phase 2
UB-421
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for HIV-1-infection.
Phase 2Last checked: Nov 19, 2026Latest source record: May 10, 2023 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
14
Any phase or sponsor naming "UB-421"
First trial start
2024
Mar 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "UB-421", any sponsor or status.
Conditions studied
As listed on its trial records.
- HIV-1-infection
Approved drugs for the same conditions: HIV · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "UB-421" as an intervention, largest first.
- UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 InfectionPivotal-lookingStatus unknown
United BioPharmaIndustry
NCT04406727 · 50 participants (planned) · Start Dec 1, 2023 · Primary completion Jun 30, 2026
Drug: UB-421 · For: HIV-1 Infection
UBP Greater China (Shanghai) Co., LtdIndustry
NCT04404049 · 39 participants (planned) · Start Dec 1, 2023 · Primary completion Jun 30, 2024
Drug: UB-421(25 mg/kg) Q2W; UB-421(25 mg/kg) Q4W · For: HIV-1-infection
United BioPharmaIndustry
NCT03743376 · 31 participants · Start Dec 12, 2018 · Primary completion Oct 15, 2020
Drug: UB-421(25 mg/kg) Q2W; UB-421(25 mg/kg) Q4W · For: HIV-1 Infection
Sites: Kaohsiung City, Taiwan; Taipei, Taiwan · 3 sites in all
United BiomedicalIndustry
NCT01668043 · 29 participants · Start Sep 2012 · Primary completion Mar 2014
Drug: Antibody UB-421 · For: HIV-1 Infection in Adults
Sites: Taipei, Taiwan; Kaohsiung City, Taiwan
United BioPharmaIndustry
NCT02369146 · 29 participants · Start Jun 2015 · Primary completion Jul 2016
Drug: UB-421 · For: HIV-1 Infection
Sites: Taipei, Taiwan
- A Proof of Concept Study to Evaluate the Effect of UB-421 in Combination With Chidamide on HIV Viral ReservoirNot yet recruiting
UBP Greater China (Shanghai) Co., LtdIndustry
NCT04985890 · 20 participants (planned) · Start Mar 2024 · Primary completion Dec 2026
Drug: UB-421 · For: HIV-1-infection
United BiomedicalIndustry
NCT01140126 · 20 participants · Start May 2010 · Primary completion Jul 2011
Drug: Antibody UB-421 · For: HIV-1 Infection in Adults (Asymptomatic)
Sites: Taipei, Taiwan; Kaohsiung City, Taiwan
United BioPharmaIndustry
NCT04620291 · 18 participants (planned) · Start Dec 31, 2023 · Primary completion Dec 31, 2025
Drug: UB-421 SC · For: HIV-1-infection
United BioPharmaIndustry
NCT04620304 · 15 participants · Start Jan 1, 2021 · Primary completion May 25, 2022
Drug: UB-421 SC(dB4C7C22-6 mAb) · For: HIV-1 Infection
Sites: Kaohsiung City, Taiwan
United BioPharmaIndustry
NCT05056974 · 11 participants · Start Dec 2, 2021 · Primary completion Feb 1, 2023
Drug: UB-421; chidamide · For: HIV-1 Infection
Sites: Kaohsiung City, Taiwan, Taiwan
Newest research
PubMed records naming it or its code names, newest first.
- Sustained virologic suppression of multidrug-resistant HIV in an individual treated with anti-CD4 domain 1 antibody and lenacapavir.
Rai MA, Blazkova J, Kardava L, et al. · Nat Med 2025
- Ex vivo sensitivity to broadly neutralizing antibodies and anti-CD4 antibody UB-421 of infectious viral isolates from people living with multidrug-resistant HIV.
Rai MA, Blazkova J, Justement JS, et al. · EBioMedicine 2024
- Emerging drugs for the treatment of HIV/AIDS: a review of 2019/2020 phase II and III trials.
Piscaglia M, Cossu MV, Passerini M, et al. · Expert Opin Emerg Drugs 2021
- Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption.
Wang CY, Wong WW, Tsai HC, et al. · N Engl J Med 2019
Also in development for HIV-1-infection
- GS-3242Phase 33 trials
Gilead Sciences · HIV-1-infection, HIV-1 Infection
- LEN FDCPhase 33 trials
Gilead Sciences · HIV-1-infection, HIV-1 Infection
- TAFPhase 33 trials
Gilead Sciences · HIV-1-infection, Chronic Hepatitis B
- TeropavimabTAB, GS-5423Phase 33 trials
Gilead Sciences · HIV-1 Infection, HIV Infections, HIV-1-infection
- ZinlirvimabGS-2872, ZABPhase 33 trials
Gilead Sciences · HIV-1 Infection, HIV Infections, HIV-1-infection
- OBRPhase 32 trials
Gilead Sciences · HIV-1-infection
- TMB-365TMB-380, VRC07523LSPhase 23 trials
TaiMed Biologics Inc. · HIV-1-infection, HIV -1 Infection
- CAP256V2LSPhase 21 trial
Gilead Sciences · HIV-1-infection
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.